SINGAPORE, 7 February 2023 – VFlowTech, the Singapore-based provider of vanadium-based redox flow batteries, has raised US$10 million in a Series A funding round. Led by Japan-based venture capital (VC)...
DSMB supports continuation of Anthera Phase 2 impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera’s Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol, without change.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.